What are chikungunya symptoms? CDC issues travel warning for China amid outbreak
This comes as more than 7,000 cases of the mosquito-borne virus were reported in the Guangdong province of China, forcing the authorities to put in measures similar to the ones taken during the COVID-19 pandemic period, as per BBC.
Among the worst-affected regions in the country is the city of Foshan, where chikungunya patients have been ordered to stay in the hospital until they test negative. They will be discharged at the end of a week-long stay, and their beds are being protected using mosquito nets.
Chikungunya: What to know?
The viral disease is transmitted mainly through the Aedes mosquitoes. It is caused by the chikungunya virus (CHIKV), which is an RNA virus in the alphavirus genus of the Togaviridae family, as per the World Health Organization (WHO).
CHIKV was identified for the first time in the United Republic of Tanzania in 1952, while major outbreaks have been reported in America, Asia, and Africa.
A study that came out in Nature in June this year, estimated that around 35.3 million people get infected by Chikungunya on an annual basis across 180 countries and regions. It leads to nearly 3,700 deaths, which is 0.01% of the total cases, as per TIME magazine. The latest outbreak in China has been attributed to imported cases.
Liu Qiyong, China CDC's chief expert in vector-borne disease control, told CGTN, 'With the virus spreading globally, imported cases have inevitably reached China.'
Chikungunya symptoms
The WHO states that chikungunya symptoms are quite similar to dengue and Zika, thus making it difficult to diagnose the disease and accurately determine the total number of infected persons.
Also read: Chikungunya outbreak: China on high alert as Guangdong battles over 7,000 cases amid COVID like strict measures
Some of the most common symptoms of Chikungunya include high fever, joint pain, headache, muscle pain, as well as joint swelling and rashes.
The symptoms usually appear around 4-8 days after the patient is bitten by the infected mosquito. At first, the person gets to witness an 'abrupt onset of fever, frequently accompanied by severe joint pain,' as per the WHO.
Notably, the joint pain is often debilitating and can last anywhere from a few days to weeks, months, and even years in some cases.
While most of the patients completely recover from the infection, there are cases of eye, heart, and neurological complications that have come up due to the CHIKV infection.
FAQs:
1. Why CDC has issued a warning for China?
CDC's Level 2 alert, which is designated as 'Practice Enhanced Precautions', came out after China marked over 7,000 cases of chikungunya infections.
2. How are chikungunya patients treated?
No specific antiviral treatment is available for the chikungunya virus infections. Usually, doctors give antipyretic and analgesic medications, like paracetamol, for fever and pain, as per the WHO. Also, there are two chikungunya vaccines that have received regulatory approvals, but these are not widely available.
3. Is chikungunya fatal?
Severe symptoms and deaths from the viral disease are rare, occurring mostly among young children or elderly people who have co-existing health problems.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
an hour ago
- Economic Times
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Synopsis Novo Nordisk warned of ongoing competition from copycat versions of its obesity drug Wegovy and signaled possible layoffs due to slowing sales growth, especially in the U.S. The Danish drugmaker, which lost $95 billion in market value after cutting full-year forecasts, said over one million Americans still use compounded GLP-1 drugs despite a U.S. ban. Reuters Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly, the Danish drugmaker warned on Wednesday. Novo, which became Europe's most valuable company worth $650 billion last year on booming sales of Wegovy, is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. It has warned of far slower growth this year - in part due to compounders who have been allowed to make copycat medicines based on the same ingredients as Wegovy due to shortages. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since. The shares were down 3.4% at 1350 GMT. The slide is a huge and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the firm is eyeing potential cost-cutting measures. "We probably won't be able to avoid layoffs," outgoing CEO Lars Fruergaard Jorgensen told Danish broadcaster DR. "When you have to adjust a company, there are some areas where you have to have fewer people, some (areas) where you have to be smaller." He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs - known as GLP-1 receptor agonists - was of "equal size to our business" and compounded versions of Wegovy were sold at a "much lower price point". In May, the company said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million U.S. patients were still using compounded GLP-1s and that Novo's lowered outlook has "not assumed a reduction in compounding" this year. "The obesity market is volatile," Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of Novo's new full-year guidance range would be for "unforeseen events", such as stronger pricing pressure in the U.S. than forecast, he said. The lower end of the range would imply sales around 150 billion Danish crowns ($23 billion) in the second half of 2025, compared with 157 billion in the same period last year. ENCOURAGING PRESCRIPTION DATA Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest U.S. prescription data for Wegovy. While the drug was overtaken earlier this year by rival Lilly's Zepbound in terms of U.S. prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36% in the U.S. and more than quadrupled in markets outside the U.S. compared to a year ago, Novo said. While Wegovy's U.S. pricing held steady in the quarter, the company expected deeper erosion in the key U.S. market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo was expanding its U.S. direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar "cash sales" directly to patients, outside of insurance channels, in some markets outside the United States. COST CUTS The company reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said Novo was acting to "ensure efficiencies in our cost base" as the company announced it would terminate eight R&D projects. "There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence," Jefferies analysts said in a note. Investors have questioned whether Novo can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendation on the stock since last week. Shares in Novo plunged 30% last week - their worst weekly performance in over two decades. Sales rose 18% in the second quarter to 76.86 billion Danish crowns, below analysts' initial expectations.
Time of India
2 hours ago
- Time of India
Flights to 3 cities from Nagpur discontinued
Nagpur: In times when Nagpur airport is set for a transformation, flights to three destinations from the city — Lucknow, Nashik, and Kolhapur — have been discontinued. Star Air, which introduced a flight to Kolhapur, withdrew the service within two months of its introduction. It was learnt that the service was discontinued due to poor response. The passenger load was inadequate, and most of the days, it remained half or even below than that which was far below viability levels, said airport sources. Flights to Nashik and Lucknow were operated by IndiGo Airlines. The airline cited 'operational reasons' as the cause for withdrawing the services, said the sources. Nagpur airport is currently run by Mihan India Limited (MIL), a joint venture between state govt's Maharashtra Airport Development Company (MADC) and Airports Authority of India (AAI). The airport is set to be taken over by GMR Group. The takeover hinges on the Union cabinet approving the transfer of AAI's assets to MIL. After that MIL will officially transfer the airport to GMR. There were plans to start flights to Jaipur, but no new flight has been introduced, said sources. During Covid pandemic, flight to Chennai was withdrawn, and the service has not been restarted yet. Sources in the aviation sector say the lack of aircraft with the operators has led to decisions on reducing flights from smaller centres. The next flight schedule is expected to be announced by airlines in October. The MIL has been insisting the airlines explore service to new sectors from Nagpur, said a source.
Time of India
2 hours ago
- Time of India
KSRTC buses, stations undergo transformation under waste free Kerala campaign
Thiruvananthapuram: Local self govt minister M B Rajesh said that as part of waste-free Kerala campaign, a remarkable transformation was taking place in KSRTC buses and bus stations. He was speaking at the inauguration of Haritha Sangamam —a one-day workshop, jointly organised by Haritha Keralam Mission and KSRTC on Wednesday. As part of the waste-free campaign, cleaning activities are conducted every Saturday in the offices of the transport department and bus stations. The minister also mentioned that bins were being installed inside the buses and waste was being processed accordingly. Transport minister Ganesh Kumar said it was essential for bus stations to be clean and KSRTC employees have been able to make this practical. "Bus stations are places with the highest footfall in a day. If such places are clean, our land will also be clean. By providing facilities like clean restaurants and restrooms, KSRTC has been able to regain passengers lost during the Covid-19 period," the minister said. On Aug 21 chief minister would flag-off of KSRTC vehicles with the best facilities available in the country. There would also be a KSRTC expo at Kanakakunnu on Aug 22, said the minister. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Free P2,000 GCash eGift UnionBank Credit Card Apply Now Undo The workshop held at Kamaleswaram Convention Centre was attended by KSRTC chairman P S Pramoj Shankar, Nava Keralam action plan coordinator T N Seema, Kerala solid waste management project (KSWMP) director Divya S Iyer and Kamaleswaram ward councillor V Vijayakumari.
